Renerve Ltd Secures Up to A$5M Funding Facility for US Growth
ReNerve locks in up to A$5 million funding facility to fuel commercial expansion
ReNerve (ASX:RNV) has entered into a convertible note funding facility with RiverFort Global Opportunities PCC Ltd for up to A$5 million, giving the medical device company staged access to capital over a three-year availability period.
The facility opens with an initial drawdown of approximately A$1.6 million in gross proceeds, delivering around A$1.361 million in net cash after the initial issue discount, drawdown fee and legal costs.
For investors, the significance lies in the structure. Rather than a single large equity raise, the staged design lets management draw funds in tranches as commercial milestones are reached, funding US sales growth and product launches while managing the pace of dilution.
When big ASX news breaks, our subscribers know first
Inside the facility structure
Each drawdown is issued as convertible securities with a face value of A$1 per security, with the initial drawdown issued at a 10% discount to face value. The convertible securities comprising the first drawdown will be issued using the Company’s available placement capacity under ASX Listing Rule 7.1.
The initial capital and obligations under the facility are secured by a first-ranking security interest over all present and after-acquired property of the Company, including its entitlement to future R&D Tax Incentive proceeds.
The table below summarises the key commercial terms disclosed in the announcement.
| Term | Detail |
|---|---|
| Total facility | Up to A$5M |
| Availability period | 3 years |
| Initial drawdown (gross) | ~A$1.6M |
| Net proceeds | ~A$1.361M |
| Face value per security | A$1, initial drawdown at 10% discount to face value |
| Maturity | 18 months from each drawdown |
| Repayment | Monthly cash instalments commencing 6 months after each drawdown |
| Fixed placing price (first drawdown) | 10.0849 cents (30% premium to 5-day VWAP) |
| Drawdown fee | 4% (cash) or 5% (shares), Company’s election |
| Options to RiverFort | 20% of drawdown amount, exercisable at 10% premium to reference price, 36-month term |
Several secondary protections and terms also apply to the facility:
-
Maximum dilution for the first drawdown only is 16,054,394 shares. Additional shares and options may be issued in connection with future drawdowns, fee payments, option exercises and conversions, so this cap applies to the first drawdown alone.
-
Options issued to RiverFort in connection with the first drawdown are subject to approval at the Company’s next general meeting. Future issuances of securities under the facility will be subject to shareholder approval where required.
-
If a monthly instalment is not paid in cash, the investor is granted conversion rights for the unpaid amounts at 90% of the 5-day VWAP prior to conversion.
-
Default interest of 3% per month may accrue on outstanding amounts in the event of an uncured default.
-
Amounts received under the R&D Tax Incentive may be required to be applied toward repayment of the facility.
-
The facility is secured by a first-ranking security interest over all present and after-acquired property of the Company.
What the funding unlocks for ReNerve
The proceeds are earmarked for continued commercialisation, including expansion of ReNerve’s product portfolio, US sales and distribution activities, and broader market development initiatives. The staged structure is designed to align funding with commercial progress, allowing management to draw capital as required while working to manage dilution and cash flow.
For investors weighing the commercialisation runway, the facility provides funding capacity behind the company’s growth agenda without committing to a single large dilutive raise upfront.
CEO Commentary
“The staged structure allows us to access capital as required, while supporting the Company’s ongoing commercialisation activities and managing dilution and cash flow,” said Dr Julian Chick, CEO & Managing Director. “This facility provides additional funding capacity as we continue to drive sales growth, support new product launches and pursue regulatory and commercial opportunities across key international markets.”
Understanding convertible note facilities
For RNV shareholders, the relevance is that funding can be aligned with commercial progress. The company gains the option to access capital as needed rather than diluting the register through one large raise, though the ultimate dilution depends on how each drawdown is repaid or converted.
The commercial backdrop and growth story
The funding arrives against a backdrop of continued commercial traction since ReNerve’s 2022 product launch. The Company reported 53% revenue growth in FY25, reaching $271k in sales, with YTD FY2026 sales revenues showing further significant increases across the portfolio.
ReNerve’s most recent quarterly update showed 79% quarter-on-quarter revenue growth in Q3 FY26, with the company recording its first-ever $100,000 sales month in March 2026 and expanding its US distributor network to 21 active partners.
The broader opportunity is sizeable. The global nerve repair market was valued at US$1.6 billion in 2024 and is projected to reach US$6.2 billion by 2031, according to the Global Nerve Repair Biomaterials Market Research Report.
At the centre of the portfolio is the FDA-cleared NervAlign® Nerve Cuff, a bioabsorbable protective wrap. A clinical study reported post-surgical pain scores dropping from 7.1 to 0.4 in patients treated with the device, compared with 7.1 to 3.3 without it.
ReNerve’s on-market product range currently includes:
-
NervAlign® Nerve Cuff – a bioabsorbable protective wrap naturally absorbed within six months of surgery.
-
Empliq™ Deep Dermal – a deep dermal product used in reconstructive and cosmetic surgical cases.
-
Empliq™ Amniotic tissue ranges – three amniotic tissue product ranges used to aid wound healing.
The company is also advancing a pipeline of in-development products, including the NervAlign® Nerve Conduit Range, Nerve Guide Matrix and Bionic Nerve technologies.
The next major ASX story will hit our subscribers first
What comes next
The three-year availability period means further drawdowns may follow, subject to shareholder approval where required and compliance with the ASX Listing Rules. The Company has stated it intends to seek shareholder approval, where required, for future issuances of securities under the facility.
Management has indicated the funds will support US distribution, new product launches, and regulatory and commercial opportunities across key international markets, extending the commercialisation strategy that has driven recent sales growth.
Key international markets are already being activated: ReNerve executed a Malaysian distribution agreement with Kuala Lumpur-based UG Medical Services following MDA regulatory clearance in 2026, unlocking a 33-million-person market as part of an Asia-Pacific expansion running parallel to the US sales push.
Don’t Miss the Next Healthcare Breakout on the ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ investors who stay ahead of the market the moment announcements hit. Click the “Free Alerts” button at StockWire X to start receiving alerts today.